Immunotherapy before surgery significantly improves outcomes of patients with melanoma: NEJM Dr. Kamal Kant Kohli10 March 2023 10:00 AM ISTUCLA Jonsson Comprehensive Cancer Center researchers have found in a multicenter trial that Immunotherapy before surgery significantly improves...
Merck scraps another prostate cancer study as Keytruda therapy disappoints Ruchika Sharma1 March 2023 2:15 PM ISTNew Delhi: Merck & Co said on Tuesday it will stop a late-stage trial evaluating a combination therapy with its cancer drug Keytruda after interim...
Wellmarker Bio enters clinical trial collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA Ruchika Sharma9 Feb 2023 2:15 PM ISTWM-A1-3389 is a novel therapeutic antibody targeting a new immune checkpoint protein discovered by Wellmarker Bio and has demonstrated efficacy across...
MSD bags DCGI nod for Keytruda to treat cervical cancer Ruchika Sharma25 Jan 2023 12:30 PM ISTMumbai: Drugs Controller General of India (DCGI) has approved Keytruda (pembrolizumab), MSD’s anti-PD-1 therapy, for the treatment of persistent,...
Drug combination for stage IV melanoma shows success in trial Dr. Kamal Kant Kohli17 Jan 2023 10:00 AM ISTA new multidrug treatment for patients with stage IV melanoma has proven effective after a three-year clinical trial at the University of Colorado...
Merck, Antengene collaborate to test Keytruda, ATG-037 combo for solid tumors in phase 1 trial Ruchika Sharma31 Dec 2022 11:30 AM ISTATG-037 is an orally available, small molecule CD73 inhibitor.
Merck secures USFDA priority review for PADCEV with KEYTRUDA for treatment of Urothelial Cancer Ruchika Sharma22 Dec 2022 3:21 PM ISTPADCEV (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface...
Prostate cancer treatment with pembrolizumab and olaparib yields promising outcomes: Study Dr. Kamal Kant Kohli12 Oct 2022 7:30 PM ISTUSA: According to a research published in the European Urology journal, pembrolizumab plus olaparib exhibited an antitumor effect and predicted...
Phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer shows positive headline results: GSK Ruchika Sharma9 Oct 2022 2:00 PM ISTJemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands...
Preoperative Pembrolizumab may not increase complications during or after oral cavity cancer surgery Dr. Kamal Kant Kohli8 Sept 2022 4:00 PM ISTPembrolizumab is sold under the brand name Keytruda and is an antibody used in cancer immunotherapy that treats a variety of cancers, including cancer...
Merck Keytruda fails head and neck cancer trial Rahul Verma21 July 2022 5:00 PM ISTMerck, known as MSD outside the United States and Canada, has announced that the Phase 3 KEYNOTE-412 trial evaluating KEYTRUDA (pembrolizumab),...
Merck Keytruda fails in head and neck cancer trial Ruchika Sharma21 July 2022 2:30 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
